Biohaven CEO Vlad Coric

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

With one mi­graine drug on the mar­ket, Bio­haven has gone big with its next phase of growth, tar­get­ing ma­jor neu­rode­gen­er­a­tive dis­eases in Alzheimer’s and ALS. The for­mer ef­fort has al­ready gone up in smoke, and a new fail­ure else­where in the pipeline could now bode poor­ly for the lat­ter.

Bio­haven’s verdiper­stat failed to out­per­form place­bo in re­duc­ing the symp­toms of pa­tients with mul­ti­ple sys­tem at­ro­phy (MSA), a rare and fa­tal neu­rode­gen­er­a­tive dis­or­der, ac­cord­ing to a “fo­cused analy­sis” of the drug’s Phase III tri­al in that dis­ease toplined Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.